Celltrion Group is seeking further growth and an improvement in profit margins through the setting up of its own direct global sales, marketing and distribution system for new products, and for its already commercialized lines if it is unable to find "win-win" strategies with existing partners for these.
Celltrion said it aims to begin with the direct handling worldwide of a new subcutaneous formulation of its biosimilar infliximab Remsima, which is undergoing regulatory review in Europe (Also see "Celltrion Plans EU Filing For Remsima SC As Phase III Completed" - Scrip, 30 August, 2018.)